FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 322:1175-1182 April 26, 1990 Number 17 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Interleukin-2 is a major growth factor for activated T lymphocytes, and antibodies reacting with the Tac-chain component of the interleukin-2 receptor can prevent allograft rejection in animals. Because Tac chains are expressed only on a small fraction of activated lymphocytes, monoclonal antibodies against the interleukin-2 receptor may offer a more specific means of immunosuppression than polyclonal antilymphocyte globulin in prophylaxis against graft rejection. Therefore, we compared the immunosuppressive effect of 33B3.1, a rat monoclonal antibody against the human Tac chain, with the effect of a rabbit polyclonal antithymocyte globulin in a randomized study of 100 recipients of first renal transplants. Injections of 33B3.1 (10 mg per day) were tolerated well, whereas major side effects in 15 of 47 patients (32 percent) receiving antithymocyte globulin required discontinuation of treatment before day 14. The incidence of rejection episodes was not statistically different in the two groups at days 14, 30, 60, and 90 after transplantation. Patient and graft survival was also equal in the two groups at one year (96 and 85 percent, respectively, in both groups), and graft function was similar. The total number of infectious episodes within the first three months was lower in the 33B3.1 group than in the antithymocyte group (47 vs. 72). The drop in peripheral-blood lymphocyte concentrations was significantly larger in the patients treated with antithymocyte globulin. The level of circulating Tac-chain-bearing lymphocytes remained below 1 percent during 33B3.1 treatment, as compared with 4 to 5 percent during antithymocyte-globulin treatment (P not significant). We conclude that 33B3.1 is as effective as antithymocyte globulin in the prevention of renal-transplant rejection, and its use results in fewer infections and side effects.

Source Information

Service de Nephrologie et d'Immunologie Clinique, Centre Hospitalier Regional Universitaire, Nantes, France.

This article has been cited by other articles:

• Abou-Ayache, R., Buchler, M., Lepogamp, P., Westeel, P.-F., Le Meur, Y., Etienne, I., Lobbedez, T., Toupance, O., Caillard, S., Goujon, J.-M., Bergougnoux, L., Touchard, G. (2008). CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. Nephrol Dial Transplant 23: 2024-2032 [Abstract] [Full Text]  
• Pascual, J., Marcen, R., , J. O. (2001). Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab. Nephrol Dial Transplant 16: 1756-1760 [Full Text]  
• GIRAL, M., NGUYEN, J. M., DAGUIN, P., HOURMANT, M., CANTAROVICH, D., DANTAL, J., BLANCHO, G., JOSIEN, R., ANCELET, D., SOULILLOU, J. P. (2001). Mycophenolate Mofetil Does Not Modify the Incidence of Cytomegalovirus (CMV) Disease after Kidney Transplantation but Prevents CMV-Induced Chronic Graft Dysfunction. J. Am. Soc. Nephrol. 12: 1758-1763 [Abstract] [Full Text]  
• TRAN, H. T. B., ACHARYA, M. K., MCKAY, D. B., SAYEGH, M. H., CARPENTER, C. B., AUCHINCLOSS, H. JR., KIRKMAN, R. L., MILFORD, E. L. (2000). Avoidance of Cyclosporine in Renal Transplantation: Effects of Daclizumab, Mycophenolate Mofetil, and Steroids. J. Am. Soc. Nephrol. 11: 1903-1909 [Abstract] [Full Text]  
• Gagne, K., Brouard, S., Giral, M., Sebille, F., Moreau, A., Guillet, M., Bignon, J.-D., Imbert, B.-M., Cuturi, M.-C., Soulillou, J.-P. (2000). Highly Altered V{beta} Repertoire of T Cells Infiltrating Long-Term Rejected Kidney Allografts. J. Immunol. 164: 1553-1563 [Abstract] [Full Text]  
• Maes, B. D., Vanrenterghem, Y. F. (1999). Anti-interleukin-2 receptor monoclonal antibodies in renal transplantation. Nephrol Dial Transplant 14: 2824-2826 [Full Text]  
• Zheng, X. X., Steele, A. W., Hancock, W. W., Kawamoto, K., Li, X. C., Nickerson, P. W., Li, Y., Tian, Y., Strom, T. B. (1999). IL-2 Receptor-Targeted Cytolytic IL-2/Fc Fusion Protein Treatment Blocks Diabetogenic Autoimmunity in Nonobese Diabetic Mice. J. Immunol. 163: 4041-4048 [Abstract] [Full Text]  
• GUMMERT, J. F., IKONEN, T., MORRIS, R. E. (1999). Newer Immunosuppressive Drugs: A Review. J. Am. Soc. Nephrol. 10: 1366-1380 [Abstract] [Full Text]  
• GAO, Z., ZHONG, R., JIANG, J., GARCIA, B., XING, J. J., WHITE, M. J., LAZAROVITS, A. I. (1999). Adoptively Transferable Tolerance Induced by CD45RB Monoclonal Antibody. J. Am. Soc. Nephrol. 10: 374-381 [Abstract] [Full Text]  
• Benoist, J.-F., Orbach, D., Biou, D. (1998). False increase in C-reactive protein attributable to heterophilic antibodies in two renal transplant patients treated with rabbit antilymphocyte globulin. Clin. Chem. 44: 1980-1985 [Abstract] [Full Text]  
• Vincenti, F., Kirkman, R., Light, S., Bumgardner, G., Pescovitz, M., Halloran, P., Neylan, J., Wilkinson, A., Ekberg, H., Gaston, R., Backman, L., Burdick, J., The Daclizumab Triple Therapy Study Group, (1998). Interleukin-2-Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation. NEJM 338: 161-165 [Abstract] [Full Text]  
• Suthanthiran, M., Strom, T. B. (1994). Renal Transplantation. NEJM 331: 365-376 [Full Text]  
• Dantal, J., Bigot, E., Bogers, W., Testa, A., Kriaa, F., Jacques, Y., de Ligny, B. H., Niaudet, P., Charpentier, B., Soulillou, J. P. (1994). Effect of Plasma Protein Adsorption on Protein Excretion in Kidney-Transplant Recipients with Recurrent Nephrotic Syndrome. NEJM 330: 7-14 [Abstract] [Full Text]  
• Chandler, C., Passaro, E. Jr (1993). Transplant Rejection: Mechanisms and Treatment. Arch Surg 128: 279-283 [Abstract]  
• (1990). TWO NOVEL APPROACHES IMPROVE SUCCESS OF RENAL TRANSPLANTS. JWatch General 1990: 2-2 [Full Text]